1. Inicio
  2. Publicaciones
  3. Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer.

Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Cabrera S
  • Gómez-Hidalgo NR
  • García-Pineda V
  • Bebia V
  • Fernández-González S
  • Alonso P
  • Rodríguez-Gómez T
  • Fusté P
  • Gracia-Segovia M
  • Lorenzo C
  • Chacon E
  • Roldan Rivas F
  • Arencibia O
  • Martí Edo M
  • Fidalgo S
  • Sanchis J
  • Pantoja-Garrido M
  • Martínez S
  • Peiró R
  • Escayola C
  • Oliver-Pérez MR
  • Aghababyan C
  • Tauste C
  • Morales S
  • Torrent A
  • Utrilla-Layna J
  • Fargas F
  • Calvo A
  • Aller de Pace L
  • Gil-Moreno A
  • Spain-GOG and the MULTISENT Study Group

Abstract

BACKGROUND: Sentinel lymph node (SLN) biopsy has recently been accepted to evaluate nodal status in endometrial cancer at early stage, which is key to tailoring adjuvant treatments. Our aim was to evaluate the national implementation of SLN biopsy in terms of accuracy to detect nodal disease in a clinical setting and oncologic outcomes according to the volume of nodal disease. PATIENTS AND METHODS: A total of 29 Spanish centers participated in this retrospective, multicenter registry including patients with endometrial adenocarcinoma at preoperative early stage who had undergone SLN biopsy between 2015 and 2021. Each center collected data regarding demographic, clinical, histologic, therapeutic, and survival characteristics. RESULTS: A total of 892 patients were enrolled. After the surgery, 12.9% were suprastaged to FIGO 2009 stages III-IV and 108 patients (12.1%) had nodal involvement: 54.6% macrometastasis, 22.2% micrometastases, and 23.1% isolated tumor cells (ITC). Sensitivity of SLN biopsy was 93.7% and false negative rate was 6.2%. After a median follow up of 1.81 years, overall surivial and disease-free survival were significantly lower in patients who had macrometastases when compared with patients with negative nodes, micrometastases or ITC. CONCLUSIONS: In our nationwide cohort we obtained high sensitivity of SLN biopsy to detect nodal disease. The oncologic outcomes of patients with negative nodes and low-volume disease were similar after tailoring adjuvant treatments. In total, 22% of patients with macrometastasis and 50% of patients with micrometastasis were at low risk of nodal metastasis according to their preoperative risk factors, revealing the importance of SLN biopsy in the surgical management of patients with early stage EC.

© 2023. The Author(s).

Datos de la publicación

ISSN/ISSNe:
1068-9265, 1534-4681

ANNALS OF SURGICAL ONCOLOGY  Springer New York LLC

Tipo:
Article
Páginas:
7653-7662
Factor de Impacto:
1,158 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • TRIAL; LYMPHADENECTOMY; MULTICENTER; METASTASIS; CARCINOMA; STEP

Campos de estudio

Proyectos asociados

INDIVIDUALIZED PERIOPERATIVE HEMODYNAMIC GOAL-DIRECTED THERAPY IN MAJOR ABDOMINAL SURGERY (IPEGASUS-TRIAL).

Investigador Principal: ÓSCAR DÍAZ CAMBRONERO

IPEGASUS . 2017

INVESTIGACIÓN CLÍNICA PARA LA EVALUACIÓN DEL EFECTO DE PAPILOCARE® EN LA NORMALIZACIÓN DE LAS ALTERACIONES CITOLÓGICAS DEL CUELLO DEL ÚTERO CAUSADAS POR EL VPH.

Investigador Principal: MARTA GURREA SOTERAS

PAPILOBS . 2019

ENSAYO CLÍNICO PALOMA II: ENSAYO CLÍNICO ALEATORIZADO, ABIERTO, MULTICÉNTRICO DE GRUPOS PARALELOS Y CON GRUPO CONTROL, PARA EXPLORAR LA EFICACIA DEL GEL VAGINAL PAPILOCARE® EN LA REPARACIÓN DE LA MUCOSA CERVICAL CON LESIONES CAUSADAS POR VIRUS PAPILOMA HUMANO.

Investigador Principal: MARTA GURREA SOTERAS

PALOMA II . 2019

ESTUDIO COMPARATIVO EN EL TRATAMIENTO ADYUVANTE EN PACIENTES CON CÁNCER DE OVARIO AVANZADO: QT INTRAPERITONEAL VS INTRAVENOSA: ESTUDIO CAOPI.

Investigador Principal: PABLO PADILLA ISERTE

PPI-QUI-2020-01 . 2020

Estudio prospectivo en la valoración del uso del Movilizador Uterino en el Cáncer de Endometrio estadio Inicial: estudio pro MUCEI.

Investigador Principal: PABLO PADILLA ISERTE

Estudio pro MUCEI . 2021

Evaluation of the OSNA method for the detection of lymph node metastases in women with cervical cancer - A feasibility study.

Investigador Principal: SUSANA LÓPEZ AGULLÓ

CP-OSNA-CeC-210 . 2022

Evaluation of the OSNA method for the detection of lymph node metastases in women with endometrial cancer ‐ A feasibility study.

Investigador Principal: SUSANA LÓPEZ AGULLÓ

CP-OSNA-EC-210 . 2022

Assessment of the prognostic impact of the published European Society of Gynecologic Oncology quality indicators for advanced ovarian cancer surgery.

Investigador Principal: MARTA ARNÁEZ DE LA CRUZ

2023-332-1 . 2023

SENECA Study: Staging Endometrial caNcer based on molEcular ClAssification.

Investigador Principal: MARTA ARNÁEZ DE LA CRUZ

2022.195 . 2023

Cita

Compartir